doi: 10.1111/liv.13654 110 ObikaMNoguchiH
Management typically involves aminosalicylates, corticosteroids, immunosuppressants, or biological therapies, depending on disease severity and extent
Table 2 shows adverse reactions (excluding hypoglycemia) that were not present at baseline, occurred more commonly in empagliflozin-treated patients than placebo-treated patients, and occurred in greater than or equal to 2% of empagliflozin-treated patients
Next, make the top layer of the pudding
For example, a novel HPLC method to monitor the levels of reduced Prx2 form was developed [87], which could prove useful for future clinical practice
regulatory status may change, and readers should check current MHRA and ClinicalTrials.gov listings for the latest information